Literature DB >> 11983635

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.

David Smith1, Carrie Dempster, Julie Glanville, Nick Freemantle, Ian Anderson.   

Abstract

BACKGROUND: In individual studies and limited meta-analyses venlafaxine has been reported to be more effective than comparator antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs). AIMS: To perform a systematic review of all such studies.
METHOD: We conducted a systematic review of double-blind, randomised trials comparing venlafaxine with alternative antidepressants in the treatment of depression. The primary outcome was the difference in final depression rating scale value, expressed as a standardised effect size. Secondary outcomes were response rate, remission rate and tolerability.
RESULTS: A total of 32 randomised trials were included. Venlafaxine was more effective than other antidepressants (standardised effect size was -0.14, 95% Cl -0.07 to -0.22). A similar significant advantage was found against SSRIs (20 studies) but not tricyclic antidepressants (7 studies).
CONCLUSIONS: Venlafaxine has greater efficacy than SSRIs although there is uncertainty in comparison with other antidepressants. Further studies are required to determine the clinical importance of this finding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11983635     DOI: 10.1192/bjp.180.5.396

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  59 in total

Review 1.  Mirtazapine versus other antidepressive agents for depression.

Authors:  Norio Watanabe; Ichiro M Omori; Atsuo Nakagawa; Andrea Cipriani; Corrado Barbui; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 2.  Second-generation antidepressants.

Authors:  G Michael Allan; Adil S Virani; Noah Ivers
Journal:  Can Fam Physician       Date:  2011-10       Impact factor: 3.275

3.  Single-action versus dual-action antidepressants.

Authors:  Rakesh Jain
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

4.  Venlafaxine for major depression.

Authors:  Andrea Cipriani; John R Geddes; Corrado Barbui
Journal:  BMJ       Date:  2007-02-03

Review 5.  Remission from depression : a review of venlafaxine clinical and economic evidence.

Authors:  Donald Han; Edward C Y Wang
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis.

Authors:  S Weinmann; T Becker; M Koesters
Journal:  Psychopharmacology (Berl)       Date:  2007-10-23       Impact factor: 4.530

Review 7.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

8.  Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.

Authors:  Alan Lenox-Smith; Liz Greenstreet; Kate Burslem; Chris Knight
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

9.  An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.

Authors:  Joachim Wernicke; Alberto Lledó; Joel Raskin; Daniel K Kajdasz; Fujun Wang
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 10.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.